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It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in 
myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of 
guidelines for the uniform reporting of clinical trial results in myeloma. This paper provides a summary of 
the current response criteria in myeloma, detailed definitions for patient populations, lines of therapy, and 
specific endpoints. We propose that future clinical trials in myeloma follow the guidelines for reporting 
results proposed in this manuscript.  
Introduction 
The treatment of myeloma has evolved rapidly in the last decade.1 The introduction of several active new 
drugs and novel targeted investigational agents has resulted in numerous active clinical trials in every stage 
of the disease. Studies are being conducted worldwide, including an increasing number of multicenter, 
international trials.2,3 It is essential that there be consistency in the conduct, analysis, and reporting of 
clinical trial results. Unless uniform reporting requirements are adhered to, it will be impossible to compare 
results across trials or to accurately determine whether reported results are valid and reliable. The goal of 
the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform 
reporting of clinical trial results in myeloma. We recognize that some compromises have to be made to 
ensure that this guidance meets requirements that are practical in most countries, academic and 
community practices, and various groups conducting clinical trials in myeloma. We propose that future 
clinical trials in myeloma follow the guidelines proposed in this manuscript.  
Lines of therapy 
A line of therapy is defined as one or more cycles of a planned treatment program.4 This may consist of one 
or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of 
treatments administered in a planned manner. For example, a planned treatment approach of induction 
therapy followed by autologous stem cell transplantation, followed by maintenance is considered one line 
of therapy. A new line of therapy starts when a planned course of therapy is modified to include other 
treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity. A new 
line of therapy also starts when a planned period of observation off therapy is interrupted by a need for 
additional treatment for the disease.  
Definition of patient populations 
The terms used to define patient populations studied should be standardized. The terms “relapsed,” and 
“refractory,” when used to describe patient populations tested in clinical trials, should adhere to the 
definitions listed in this section. These definitions are based on a recent American Society of Hematology–
Food and Drug Administration panel on endpoints in myeloma.5 We also propose that, when new clinical 
trials are initiated, these definitions be used in eligibility criteria to ensure uniformity across trials.  
Refractory myeloma 
Refractory myeloma is defined as disease that is nonresponsive while on primary or salvage therapy, or 
progresses within 60 days of last therapy. Nonresponsive disease is defined as either failure to achieve 
minimal response or development of progressive disease (PD) while on therapy. There are 2 categories of 
refractory myeloma: “relapsed-and-refractory myeloma” and “primary refractory myeloma.”  
Relapsed and refractory myeloma. 
Relapsed and refractory myeloma is defined as disease that is nonresponsive while on salvage therapy, or 
progresses within 60 days of last therapy in patients who have achieved minimal response (MR) or better at 
some point previously before then progressing in their disease course.5,6 
Primary refractory myeloma. 
Primary refractory myeloma is defined as disease that is nonresponsive in patients who have never 
achieved a minimal response or better with any therapy. It includes patients who never achieve MR or 
better in whom there is no significant change in M protein and no evidence of clinical progression as well as 
primary refractory, PD where patients meet criteria for true PD.5 On reporting treatment efficacy for 
primary refractory patients, the efficacy in these 2 subgroups (“nonresponding-nonprogressive” and 
“progressive”) should be separately specified.  
Relapsed myeloma 
Relapsed myeloma is defined as previously treated myeloma that progresses and requires the initiation of 
salvage therapy but does not meet criteria for either “primary refractory myeloma” or “relapsed-and-
refractory myeloma” categories.  
Additional qualifiers 
When possible, if a clinical trial is targeted to a specific population, it would be best to provide additional 
qualifiers that describe more precisely the population being studied, for example, “relapsed and refractory 
to immunomodulatory therapy” or “relapsed and refractory to bortezomib.” Prognostic factors, such as 
stage and cytogenetic information, should be considered as stratification factors at trial entry.  
Response criteria 
The International Myeloma Working Group (IMWG) uniform response criteria should be used in future 
clinical trials, with additional clarifications as listed in this section.7 The IMWG uniform response criteria 
were developed from the European Group for Blood and Bone Marrow Transplant/International Bone 
Marrow Transplant Registry/American Bone Marrow Transplant Registry published criteria, commonly 
referred to as the Blade criteria or the European Group for Blood and Bone Marrow Transplant criteria,8 
with revisions and improvements that aid uniform reporting. These include the addition of free light chain 
(FLC) response and progression criteria for patients without measurable disease, modification of the 
definition for disease progression for patients in complete response (CR), and addition of very good partial 
response (VGPR) and stringent response categories.  
The panel endorsed the definitions of partial response (PR), VGPR, CR, PD, and stable disease according to 
IMWG. Of note, there was unanimous consensus that PD for patients in CR should be defined as per the 
IMWG criteria. CR patients will need to progress to the same level as VGPR and PR patients to be 
considered PD. A positive immunofixation alone is therefore not sufficient.9,10 
The need for bone marrow confirmation of CR was discussed in detail, but new data showed that up to 14% 
of patients with immunofixation-negative CR may have more than or equal to 5% plasma cells in the 
marrow.11 Bone marrow confirmation is required for coding CR, and the panel recommends no change to 
the CR definition in this regard.  
The clarifications and additions to the IMWG criteria discussed in this section were recommended and 
approved by the panel. The IMWG criteria for response and progression incorporating published errata and 
clarifications,7,12,13 updated definition of stringent CR, and additional clarifications are listed in Tables 1 and 





















Table 1  
 
Immunophenotypic CR 
The panel approved a definition of immunophenotypic CR to be incorporated into the IMWG criteria (Table 
2). This requires absence of phenotypically aberrant plasma cells (clonal) in bone marrow with a minimum 




Table 2  
 
Molecular CR 
The panel approved a definition of molecular CR to be incorporated into the IMWG criteria. Molecular CR is 
defined as CR plus negative allele-specific oligonucleotide polymerase chain reaction (sensitivity 10−5; Table 
2).  
Minimal response 
The panel concurred with a recent American Society of Hematology-Food and Drug Administration panel5 
that, for patients with relapsed and/or refractory myeloma, MR should be reported separately in clinical 
trials (Table 2). When MR is reported, the specific rate of MR should be distinguished from PR or better to 
make clinical trial comparisons possible.  
Additional important clarifications 
The following clarifications to IMWG criteria were made for coding CR in patients in whom the only 
measurable disease is by serum FLC levels (Table 1). In these patients, CR requires negative serum and 
urine immunofixation plus a normal FLC ratio of 0.26 to 1.65, on 2 consecutive assessments. Similarly, to 
code VGPR in such patients, a more than 90% decrease in the difference between involved and uninvolved 
FLC levels is required on 2 consecutive assessments. These were inadvertently omitted from the IMWG 
criteria.12 Some laboratories may have a slightly different reference range for the FLC ratio than 0.26 to 
1.65. In these situations, it is appropriate to define normal FLC ratio using those used in the given 
laboratory.  
Second, the panel clarified that bone marrow criteria for PD are to be used only in patients without 
“measurable disease” as defined in the IMWG criteria7 by M protein and by FLC levels. The “lowest 
response value” in determining the nadir for PD assessment does not need to be a confirmed value.  
Third, the panel recommended that, if a patient has more than one M protein spike in the serum (or urine), 
the M protein to be followed for assessing response is only the one that meets IMWG criteria for 
“measurable” M protein level IMWG criteria.7 If more than one M protein spikes meet the criteria for 
measurable disease, then both need to be followed for response.  
Fourth, the panel agreed that magnetic resonance imaging and positron emission tomography-computed 
tomography findings will not be incorporated formally into the response criteria for purposes of assessing 
depth of response, but additional single-center studies are encouraged.15 Further validation of new aspects 
of the IMWG criteria will also be needed as agreed at the recent American Society of Hematology-Food and 
Drug Administration panel.5 
Finally, it is recommended that the time at which response assessment was conducted should be reported. 
In addition, the time to best response should also be reported.  
Reporting of efficacy results 
All efficacy results for primary endpoints should be reported only on an intent-to-treat basis. In the case of 
secondary endpoints, in addition to intent-to-treat results, results based on actual treatment received can 
also be reported. The reporting of results in subsets of patients restricted to those who completed certain 
duration of therapy should be avoided. All patients who were registered and met eligibility criteria 
regardless of whether they actually received therapy for a meaningful period (or not at all) should be in the 
denominator for all efficacy calculations. Response assessments should be performed before the next 
therapy is initiated.  
In all clinical trials, patients should be followed every 1 to 2 months until PD to enable accurate calculation 
of time to progression (TTP) and progression-free survival (PFS).  
Essential efficacy measures in phase 3 trials 
Regardless of the primary endpoint studies, all phase 3 studies should report overall survival, TTP, PFS, 
duration of response (DOR), and if possible, time to next treatment (TNT), 5-year overall survival rate, and 
10-year overall survival rate. The definitions of TTP, PFS, and DOR are listed in Table 3.7 It is particularly 
important that both TTP and PFS be reported. Where possible, details of any crossover should be provided.  
Table 3  
 
TNT 
TNT is difficult to accurately compare, except in double-blind studies, but it is clearly important to report 
TNT in future phase 3 trials. TNT is defined time from registration on trial to next treatment or death of any 
cause, whichever comes first. To accurately define TNT, next treatment should start uniformly in clinical 
practice. The consensus is that the next treatment should start when there is either clinical relapse or a 
significant paraprotein relapse.  
Clinical relapse is defined using the definition of clinical relapse in the IMWG criteria.7 In the IMWG criteria, 
clinical relapse is defined as requiring one or more of the following direct indicators of increasing disease 
and/or end-organ dysfunction that are considered related to the underlying plasma cell proliferative 
disorder:  
1. Development of new soft tissue plasmacytomas or bone lesions on skeletal survey, magnetic 
resonance imaging, or other imaging 
2. Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is 
defined as a 50% (and at least 1 cm) increase as measured serially by the sum of the products of the 
cross-diameters of the measurable lesion  
3. Hypercalcemia (> 11.5 mg/dL; > 2.875mM/L) 
4. Decrease in hemoglobin of more than 2 g/dL (1.25mM) or to less than 10 g/dL 
5. Rise in serum creatinine by more than or equal to 2 mg/dL (≥ 177mM/L) 
6. Hyperviscosity 
In some patients, bone pain may be the initial symptom of relapse in the absence of any of the features 
listed in “TNT.” However, bone pain without imaging confirmation is not adequate to meet these criteria in 
trials.  
In patients who do not have clinical relapse, a significant paraprotein relapse is defined as doubling of the 
M-component in 2 consecutive measurements separated by less than or equal to 2 months; or an increase 
in the absolute levels of serum M protein by more than or equal to 1 g/dL, or urine M protein by more than 
or equal to 500 mg/24 hours, or involved FLC level by more than or equal to 20 mg/dL (plus an abnormal 
FLC ratio) in 2 consecutive measurements separated by less than or equal to 2 months. This definition of 
“paraprotein relapse” represents the rate of rise or absolute level of increase in M protein at which the 
panel considered that myeloma therapy should be restarted in relapsing patients in clinical practice, even if 
signs and symptoms of new end-organ damage are not yet apparent.  
 
Summary and future directions 
This paper summarizes, clarifies, and updates current response criteria in myeloma. We have provided 
detailed definitions for patient populations, lines of therapy, and specific endpoints. We propose that 
future clinical trials in myeloma follow the guidelines for monitoring patients and reporting results 
proposed in this manuscript. These criteria will most probably change with time as the technology improves 
and more sensitive tests become available. We also need to develop criteria to assess the efficacy of 
therapy for earlier stages of the disease, such as smoldering multiple myeloma given the interest in 
preventive clinical trials. Finally, we need to quickly develop and validate response criteria that incorporate 
gene expression profiling and imaging techniques, such as positron emission tomography.  
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